To include your compound in the COVID-19 Resource Center, submit it here.

Pharmos Corp data

PARS also presented data from a preclinical Israeli trial showing that its SME-formulated HU-211 glaucoma drug

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE